A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

Exclusion Criteria

• •Known, current central nervous system or interstitial lung disease involvement
• •History of hemolytic anemia or positive direct antiglobulin test or active bleeding disorder
• •Chronic use of systemic corticosteroids of more than 20 mg/day of prednisone or equivalent
• •Significant cardiovascular disease
• •Other significant medical condition unrelated to the primary malignancy
• •Radiation therapy within 14 days of study treatment administration
• •Hematopoietic stem cell transplant within 90 days before the planned start of study treatment
• •Antiplatelet/anticoagulant agents within 14 days before planned start of study treatment
• •Patients sustaining major surgery at least 4 weeks prior to study enrollment
• •Use of any investigational agent or any anticancer drug within 14 days before planned start of study treatment
• •Prior anti-CD47 and anti-Signal Regulatory Protein alpha therapy
• •Active, uncontrolled bacterial, fungal, or viral infection
• •Investigator site staff directly involved in the conduct of the study and their family members